Northstar Ventures

Nanovery Limited, based in London, United Kingdom, specializes in the development of nanorobots aimed at detecting cancer mutations. Incorporated in 2018, the company leverages advances in nanotechnology, medicinal chemistry, and artificial intelligence to create a platform that enables rapid and sensitive identification of challenging disease biomarkers. These nanorobots are designed to be introduced into blood samples, where they capture circulating tumor DNA and emit a fluorescent signal, facilitating point-of-care detection. This innovative approach not only aids in the early detection of cancer but also enhances the ability to predict the evolution of cancer cells, significantly improving the chances of patient survival. Supported by academic experts, clinicians, and industry leaders, Nanovery is committed to making cancer detection more efficient and accessible.

Nanovery Limited, based in London, United Kingdom, specializes in the development of nanorobots aimed at detecting cancer mutations. Incorporated in 2018, the company leverages advances in nanotechnology, medicinal chemistry, and artificial intelligence to create a platform that enables rapid and sensitive identification of challenging disease biomarkers. These nanorobots are designed to be introduced into blood samples, where they capture circulating tumor DNA and emit a fluorescent signal, facilitating point-of-care detection. This innovative approach not only aids in the early detection of cancer but also enhances the ability to predict the evolution of cancer cells, significantly improving the chances of patient survival. Supported by academic experts, clinicians, and industry leaders, Nanovery is committed to making cancer detection more efficient and accessible.

Nanovery Limited, based in London, United Kingdom, specializes in the development of nanorobots aimed at detecting cancer mutations. Incorporated in 2018, the company leverages advances in nanotechnology, medicinal chemistry, and artificial intelligence to create a platform that enables rapid and sensitive identification of challenging disease biomarkers. These nanorobots are designed to be introduced into blood samples, where they capture circulating tumor DNA and emit a fluorescent signal, facilitating point-of-care detection. This innovative approach not only aids in the early detection of cancer but also enhances the ability to predict the evolution of cancer cells, significantly improving the chances of patient survival. Supported by academic experts, clinicians, and industry leaders, Nanovery is committed to making cancer detection more efficient and accessible.

Nanovery Limited, based in London, United Kingdom, specializes in the development of nanorobots aimed at detecting cancer mutations. Incorporated in 2018, the company leverages advances in nanotechnology, medicinal chemistry, and artificial intelligence to create a platform that enables rapid and sensitive identification of challenging disease biomarkers. These nanorobots are designed to be introduced into blood samples, where they capture circulating tumor DNA and emit a fluorescent signal, facilitating point-of-care detection. This innovative approach not only aids in the early detection of cancer but also enhances the ability to predict the evolution of cancer cells, significantly improving the chances of patient survival. Supported by academic experts, clinicians, and industry leaders, Nanovery is committed to making cancer detection more efficient and accessible.

DGS is an R&D company that specialises in the synthesis of Graphene. The company uses a unique and scalable 'bottom-up' approach to prepare Graphene that is protected by a patent application. The company was founded by Dr. Karl Coleman (Durham University) who has over 12 years experience working in the field of nanocarbons where he has published extensively.

DGS is an R&D company that specialises in the synthesis of Graphene. The company uses a unique and scalable 'bottom-up' approach to prepare Graphene that is protected by a patent application. The company was founded by Dr. Karl Coleman (Durham University) who has over 12 years experience working in the field of nanocarbons where he has published extensively.

Applied Graphene Materials is a UK-based company specializing in the production and application of graphene materials. Founded in 2010 and located in Redcar, the company manufactures graphene nanoplatelets and dispersions, which are integrated into a variety of polymer matrices, including thermoset and thermoplastic materials. Its products serve numerous applications, such as advanced composites, coatings, thermal management solutions, and functional fluids like oils and lubricants. Additionally, Applied Graphene Materials develops solutions for supercapacitors, batteries, packaging, display materials, and 3D printing. By leveraging a proprietary production process and its expertise in dispersion and product integration, the company aims to enhance the performance of existing materials across multiple sectors, positioning graphene as a transformative technology in the materials industry.